FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Mallinckrodt Pharmaceuticals Amitiza Recall

Amitiza (lubiprostone) capsules, 24 mcg, 60-count bottle, Rx only, Manufactured by: Suc…

MALLINCKRODT PHARMACEUTICALS · Bedminster, NJ

Risk level
Class II
Reported by FDA
May 29, 2019
Recall ID
D-1295-2019
Check your lot numberHow we source this data

Summary

Mallinckrodt Pharmaceuticals recalled Amitiza starting May 13, 2019. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1295-2019 on May 29, 2019. Reason: Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue. Status: Terminated.

Why it was recalled

Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.

Product description

Amitiza (lubiprostone) capsules, 24 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-240-60

Lot numbers, UPCs & expiration codes

Lot #: 3200626-61, Exp 02/2022

Where it was sold

US Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1295-2019
Classification
Class II
Status
Terminated
Recall initiated
May 13, 2019
FDA report date
May 29, 2019
Quantity
80,640 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
MALLINCKRODT PHARMACEUTICALS

Original FDA data

Every field from FDA enforcement report D-1295-2019, exactly as published.

Show all FDA fields
City
Bedminster
State
NJ
Status
Terminated
Country
United States
Event ID
82830
Address
1425 Us Highway 206
Code information
Lot #: 3200626-61, Exp 02/2022
Postal code
07921-2653
Report date
May 29, 2019
Product type
Drugs
Recall number
D-1295-2019
Classification
Class II
Recalling firm
MALLINCKRODT PHARMACEUTICALS
Product quantity
80,640 bottles
Termination date
Jul 17, 2023
Reason for recall
Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Amitiza (lubiprostone) capsules, 24 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-240-60
Distribution pattern
US Nationwide
Recall initiation date
May 13, 2019
Initial firm notification
Letter
Center classification date
May 23, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1295-2019, published May 29, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls